PATIENT AI Act Discussion Draft, AMA Issue Brief for Clinical AI Liability Released
Accountability and reimbursement for artificial intelligence (AI)-based technologies were highlighted topics of discussion last week.
The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as medical devices, and regulatory review is now pending. Because the FDA did not move to appeal this decision, the rescission is essentially a formality.
The recission comes following the decision filed March 31 in the U.S. District Court in the Eastern District of Texas, which ruled the FDA exceeded its authority and subsequently vacated the final rule. The FDA did not appeal this decision.
Once the Office of Information and Regulatory Affairs completes the regulatory review, a formal notice will be posted to the Federal Register within 60 days.
Sources:
https://www.reginfo.gov/public/do/eoDetails?rrid=1044563
https://documents.cap.org/documents/ldt-courtruling-03-31-2025.pdf
https://www.cap.org/advocacy/latest-news-and-practice-data/august-12-2025#story3

Accountability and reimbursement for artificial intelligence (AI)-based technologies were highlighted topics of discussion last week.
Lincoln, NE – November 2026 TELCOR is proud to announce the promotion of Stephanie Gonnerman to Senior Analyst, Revenue Cycle Management (RCM).
The Centers for Medicare and Medicaid Services (CMS) released a report on Oct. 20 detailing significant differences in the share of reported test...